Search - tctmd.com

Displaying 1 - 20 of 25

Sort: Relevancy | Date

News Opinion CV Team Dispatch

June 2024 Dispatch for the CV Team

L.A. McKeown

June 01, 2024

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for December 2023

Caitlin E. Cox

December 28, 2023

News Conference News AHA 2022

High-Sensitivity Troponin Testing on the Rise in the US but Still Limited

Michael O'Riordan

November 04, 2022

News Features

Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?

Michael O'Riordan

August 15, 2022

News Features

Pricey Inclisiran Is Rolling Out: a ‘Buy-and-Bill’ Model May Smooth Its Path

Michael O'Riordan

January 17, 2022

News Daily News

TCTMD’s Top 10 Most Popular Stories for December 2021

Caitlin E. Cox

December 29, 2021

News Daily News

British Medical Groups Express Concern About Inclisiran Rollout

Michael O'Riordan

December 14, 2021

News Daily News

Add-on CMS Payment Sweetens Shockwave Choice, but Cost Still Rankles

Michael O'Riordan

May 12, 2021

News Features

Roughly 80% of ESC Guideline Writers Have Financial COIs

Michael O'Riordan

April 01, 2021

News Daily News

Big Drops in LDL Cholesterol With Inclisiran, but US Clinicians Still Await Drug’s Approval

Michael O'Riordan

March 03, 2021

News Daily News

Details in Print for DanGer Design as Impella AMICS RCT Expands From Denmark to Germany

Caitlin E. Cox

May 14, 2019

News Industry News

FDA Approves Impella 5.0 and Impella LD Extended Duration of Use to 14 Days for Cardiogenic Shock Derived from AMI or Cardiomyopathy

May 13, 2019

News Daily News

PCSK9 Inhibitor Alirocumab Receives Expanded Indication for CV Event Reduction

Michael O'Riordan

April 29, 2019

News Daily News

FDA Grants Approval to TherOx for Supersaturated Oxygen Therapy in LAD STEMI

L.A. McKeown

April 04, 2019

News Daily News

FDA Approves Orsiro Ultrathin-Strut Stent for CAD

Michael O'Riordan

February 22, 2019

News Daily News

European Regulators Strike Secondary Prevention Claim for Omega-3 Drugs

Shelley Wood

December 18, 2018

News Daily News

Implantable Cardiac Monitor for High-Risk ACS Patients Wins FDA Approval

Michael O'Riordan

May 08, 2018

News Conference News ACC 2018

Bad BVS News: Analysis Points to Fast Reaction by Interventionalists to Absorb Safety Issues

Michael O'Riordan

March 11, 2018

News Daily News

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

Shelley Wood

December 26, 2017

News Daily News

Rapid Rule-Out Strategy With High-Sensitivity Troponin Shows Promise Ahead of US Commercial Availability of Test

L.A. McKeown

April 17, 2017

Advertisement

June 2024 Dispatch for the CV Team

TCTMD’s Top 10 Most Popular Stories for December 2023

High-Sensitivity Troponin Testing on the Rise in the US but Still Limited

Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?

Pricey Inclisiran Is Rolling Out: a ‘Buy-and-Bill’ Model May Smooth Its Path

TCTMD’s Top 10 Most Popular Stories for December 2021

British Medical Groups Express Concern About Inclisiran Rollout

Add-on CMS Payment Sweetens Shockwave Choice, but Cost Still Rankles

Roughly 80% of ESC Guideline Writers Have Financial COIs

Big Drops in LDL Cholesterol With Inclisiran, but US Clinicians Still Await Drug’s Approval

Details in Print for DanGer Design as Impella AMICS RCT Expands From Denmark to Germany

FDA Approves Impella 5.0 and Impella LD Extended Duration of Use to 14 Days for Cardiogenic Shock Derived from AMI or Cardiomyopathy

PCSK9 Inhibitor Alirocumab Receives Expanded Indication for CV Event Reduction

FDA Grants Approval to TherOx for Supersaturated Oxygen Therapy in LAD STEMI

FDA Approves Orsiro Ultrathin-Strut Stent for CAD

European Regulators Strike Secondary Prevention Claim for Omega-3 Drugs

Implantable Cardiac Monitor for High-Risk ACS Patients Wins FDA Approval

Bad BVS News: Analysis Points to Fast Reaction by Interventionalists to Absorb Safety Issues

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

Rapid Rule-Out Strategy With High-Sensitivity Troponin Shows Promise Ahead of US Commercial Availability of Test

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content